866-997-4948(US-Canada Toll Free)

Global (United States, European Union and China) Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2019-2025

Published By :

QYResearch

Published Date : Aug 2019

Category :

Pharmaceutical

No. of Pages : 116 Pages

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the markets growth.
In 2019, the market size of Benign Prostatic Hyperplasia (BPH) Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Benign Prostatic Hyperplasia (BPH) Drugs.

This report studies the global market size of Benign Prostatic Hyperplasia (BPH) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Benign Prostatic Hyperplasia (BPH) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals

Market Segment by Product Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors

Market Segment by Application
Men
Women

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Benign Prostatic Hyperplasia (BPH) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia (BPH) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type (2019-2025)
1.3.2 Alpha-Blocker
1.3.3 Phosphodiesterase Type-5 Inhibitors
1.3.4 5-Alpha-Reductase Inhibitors
1.4 Market Segment by Application
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2019-2025)
1.4.2 Men
1.4.3 Women
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2014-2025
2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2025
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Growth Rate by Regions
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions 2014-2019
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers

3 Market Share by Manufacturers
3.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
3.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers 2014-2019
3.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers
3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
3.6 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Alpha-Blocker Sales and Revenue (2014-2019)
4.1.2 Phosphodiesterase Type-5 Inhibitors Sales and Revenue (2014-2019)
4.1.3 5-Alpha-Reductase Inhibitors Sales and Revenue (2014-2019)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type
4.4 Benign Prostatic Hyperplasia (BPH) Drugs Price by Type

5 Market Size by Application
5.1 Overview
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

6 United States
6.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
6.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
6.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application

7 European Union
7.1 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
7.2 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
7.3 European Union Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application

8 China
8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
8.2 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
8.3 China Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application

9 Rest of World
9.1 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
9.2 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Type
9.3 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Application
9.4 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Countries
9.4.1 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
9.4.2 Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia

10 Company Profiles
10.1 Astellas Pharma
10.1.1 Astellas Pharma Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.1.5 Astellas Pharma Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.2.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.2.5 Eli Lilly Recent Development
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.3.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.3.5 GlaxoSmithKline Recent Development
10.4 Sanofi
10.4.1 Sanofi Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.4.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.4.5 Sanofi Recent Development
10.5 ADC Therapeutics
10.5.1 ADC Therapeutics Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.5.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.5.5 ADC Therapeutics Recent Development
10.6 Bayer HealthCare
10.6.1 Bayer HealthCare Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.6.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.6.5 Bayer HealthCare Recent Development
10.7 Bristol-Myers Squibb
10.7.1 Bristol-Myers Squibb Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.7.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.7.5 Bristol-Myers Squibb Recent Development
10.8 Valeant Pharmaceuticals
10.8.1 Valeant Pharmaceuticals Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.8.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.8.5 Valeant Pharmaceuticals Recent Development
10.9 Endo Pharmaceuticals
10.9.1 Endo Pharmaceuticals Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.9.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.9.5 Endo Pharmaceuticals Recent Development
10.10 Foresee Pharmaceuticals
10.10.1 Foresee Pharmaceuticals Company Details
10.10.2 Company Description and Business Overview
10.10.3 Sales, Revenue and Market Share of Benign Prostatic Hyperplasia (BPH) Drugs
10.10.4 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
10.10.5 Foresee Pharmaceuticals Recent Development

11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
11.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

12 Market Forecast
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue Forecast 2019-2025
12.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type
12.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India

13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer

List of Table

List of Tables and Figures

Figure Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Table Benign Prostatic Hyperplasia (BPH) Drugs Key Market Segments
Table Major Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered in This Report
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type 2019-2025 (K MT) & (Million US$)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Shar by Type 2014-2025
Figure Alpha-Blocker Figures
Table Major Manufacturers of Alpha-Blocker
Figure Phosphodiesterase Type-5 Inhibitors Figures
Table Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Figure 5-Alpha-Reductase Inhibitors Figures
Table Major Manufacturers of 5-Alpha-Reductase Inhibitors
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application 2019-2025 (K MT)
Figure Men Use Case
Figure Women Use Case
Figure Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2014-2025 (Million US$)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2019 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Regions 2014-2019 (K MT) & (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions 2014-2019 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2014-2019
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2014-2019
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions in 2019
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions 2014-2019 (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2014-2019
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2014-2019
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2019
Table Market Top Trends
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2014-2019) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2019
Table Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019) (Million USD)
Table Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019)
Figure Benign Prostatic Hyperplasia (BPH) Drugs Value Share by Manufacturers in 2019
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2014-2019) (USD/MT)
Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Plants/Factories Distribution
Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Area Served
Table Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table Mergers & Acquisitions, Expansion Plans
Table Global Alpha-Blocker Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Phosphodiesterase Type-5 Inhibitors Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global 5-Alpha-Reductase Inhibitors Sales and Revenue (2014-2019) (K MT) & (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2018
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2014-2019) (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type in 2018
Table Benign Prostatic Hyperplasia (BPH) Drugs Price by Type 2014-2019 (USD/MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2014-2019)
Figure Global Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2014-2019)
Figure Global Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2014-2019)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2019
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2019
Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT)
Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019)
Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT)
Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019)
Figure 2018 European Union Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type
Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT)
Table European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019)
Figure 2018 European Union Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT)
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT)
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2019
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT)
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2019
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2014-2019) (K MT)
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2014-2019)
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2014-2019) (K MT)
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2014-2019)
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2019
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2014-2019) (K MT)
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2014-2019)
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2019
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT)
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019)
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2019
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$)
Table Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019)
Figure Rest of World Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2019
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT)
Table Astellas Pharma Company Details
Table Astellas Pharma Description and Business Overview
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Astellas Pharma Recent Development
Table Eli Lilly Company Details
Table Eli Lilly Description and Business Overview
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Eli Lilly Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Description and Business Overview
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table GlaxoSmithKline Recent Development
Table Sanofi Company Details
Table Sanofi Description and Business Overview
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Sanofi Recent Development
Table ADC Therapeutics Company Details
Table ADC Therapeutics Description and Business Overview
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table ADC Therapeutics Recent Development
Table Bayer HealthCare Company Details
Table Bayer HealthCare Description and Business Overview
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Bayer HealthCare Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Description and Business Overview
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Bristol-Myers Squibb Recent Development
Table Valeant Pharmaceuticals Company Details
Table Valeant Pharmaceuticals Description and Business Overview
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Valeant Pharmaceuticals Recent Development
Table Endo Pharmaceuticals Company Details
Table Endo Pharmaceuticals Description and Business Overview
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Endo Pharmaceuticals Recent Development
Table Foresee Pharmaceuticals Company Details
Table Foresee Pharmaceuticals Description and Business Overview
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2014-2019)
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019)
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Global Market
Table Foresee Pharmaceuticals Recent Development
Figure Benign Prostatic Hyperplasia (BPH) Drugs Value Chain
Table Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT) & (Million US$)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Regions 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Regions 2019-2025
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure European Union Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast 2019-2025 (K MT)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast 2019-2025 (Million US$)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *